Anavex Life Sciences SEC filings

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KOct. 20, 2026, 4:16 p.m. ETView on SEC.gov
Other events · Financial statements and exhibits
AI summary, unreviewedAnavex Life Sciences Corp. Completes Clinical Conduct of Blarcamesine ADME and DDI Pharmacology Studies; No Financial Figures Disclosed
8-KOct. 15, 2026, 4:18 p.m. ETView on SEC.gov
Other events · Financial statements and exhibits
4Sept. 28, 2026, 9:36 p.m. ETView on SEC.gov
8-KSept. 28, 2026, 5:27 p.m. ETView on SEC.gov
Change in control · Submission of matters to a vote of security holders
8-KSept. 9, 2026, 5:17 p.m. ETView on SEC.gov
Other events
8-KSept. 2, 2026, 5:06 p.m. ETView on SEC.gov
Other events · Financial statements and exhibits
10-QAug. 28, 2026, 4:28 p.m. ETView on SEC.gov
10-QAug. 28, 2026, 4:26 p.m. ETView on SEC.gov
10-Q/AAug. 28, 2026, 4:25 p.m. ETView on SEC.gov
10-K/AAug. 28, 2026, 4:24 p.m. ETView on SEC.gov
8-KAug. 25, 2026, 8:31 a.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits
8-KAug. 17, 2026, 8:10 a.m. ETView on SEC.gov
Regulation FD disclosure · Financial statements and exhibits
8-KAug. 11, 2026, 5 p.m. ETView on SEC.gov
Regulation FD disclosure · Financial statements and exhibits
8-KAug. 3, 2026, 8:26 a.m. ETView on SEC.gov
Regulation FD disclosure · Financial statements and exhibits
SCHEDULE 13GJuly 31, 2026, 9:54 a.m. ETView on SEC.gov
8-KJuly 30, 2026, 8:15 a.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits